KDC-MN-1319 – Kodiac biolabs

Plain-language summaryIntrigue 55 / 100

Chloroprocaine (Nesacaine) is a 2-chloro analog of procaine introduced in the 1950s. The single chlorine substitution adjacent to the ester linkage dramatically accelerates plasma cholinesterase hydrolysis, producing the shortest plasma half-life of any clinical local anesthetic (roughly 21 seconds). That ultra-short systemic exposure makes chloroprocaine the safest local anesthetic for fetal exposure during obstetric epidural, and a useful agent for short-procedure spinal anesthesia in ambulatory surgical centers. The historical association with cauda equina syndrome traced to a sodium bisulfite preservative, not the drug itself; reformulation with EDTA and later preservative-free preparations resolved that concern, and chloroprocaine has returned to ambulatory spinal anesthesia as an alternative to lidocaine spinal (which carries its own transient neurologic symptoms concern). Maximum recommended doses are 11 mg/kg plain, 14 mg/kg with epinephrine. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

35/100

Decades-old ester anesthetic with the fastest offset in its class but minimal research novelty

Look, chloroprocaine is a competent clinical agent and a solved pharmacology problem. The 2-chloro substitution on the procaine backbone was figured out in the 1950s, the plasma cholinesterase hydrolysis mechanism has been characterized since at least the early 1970s, and the neurotoxicity story that blacklisted it for spinal use for two decades turned out to be a bisulfite-preservative artifact, not a compound problem. Once preservative-free formulations came back, chloroprocaine returned to ambulatory spinal anesthesia as a lidocaine alternative for short procedures where transient neurologic symptoms are a concern. That’s a clinically tidy resolution to a messy history, but it’s not a research story.

The core mechanism is sodium channel block, state-dependent, nothing exotic. Every ester and amide local anesthetic we carry does the same thing through the same pore. Chloroprocaine’s differentiation is entirely pharmacokinetic: the approximately 21-second plasma half-life is the fastest of any clinical local anesthetic, and that’s the whole argument for the compound. It matters in obstetric epidural anesthesia because fetal plasma exposure is minimized before the umbilical cord is cut. It matters in ambulatory surgery because patients discharge faster. Those are operationally real advantages, but they’re not bench-science advantages. The half-life story is fully told.

What’s genuinely interesting about chloroprocaine, in a research context, is narrow. If you’re studying plasma cholinesterase kinetics, ester hydrolysis rates, or the structure-activity relationship between halogen substitution and enzymatic clearance, chloroprocaine is a useful reference compound. The 2-chloro vs. unsubstituted procaine comparison is clean. But that work is largely done. We’re not aware of active research programs using chloroprocaine as a probe for anything that isn’t already settled pharmacology.

The evidence base is solid for what it covers: established clinical trial data for obstetric epidural, multiple comparative studies versus lidocaine and bupivacaine for ambulatory spinal, and a well-documented safety rehabilitation after the 1980s reformulation. The translational signal is real but it’s clinical utility, not frontier translation. The compound does what it does, well, in a narrow procedural niche, and the research questions that would make it genuinely interesting to a bench investigator in 2026 simply aren’t there.

Honestly, if you’re building a research library around novel mechanisms and actionable frontier compounds, chloroprocaine is reference material, not a program target. We include it for completeness in the local anesthetic class, but dont mistake clinical reliability for research priority. The score reflects where it actually sits: mature, solved, useful in its lane, not compelling as a fresh investigation target.

Novelty: 15
Mechanism promise: 15
In-category differentiation: 40
Evidence quality: 60
Translational signal: 65
Research bench value: 25

Rationale Chloroprocaine scores low on novelty and mechanism because it’s a 1950s voltage-gated sodium channel blocker with fully characterized ester hydrolysis pharmacology; its one genuine distinction is an ~21-second plasma half-life driven by the 2-chloro substitution accelerating cholinesterase cleavage, which produces real clinical differentiation in obstetric and ambulatory anesthesia but doesn’t open compelling bench-scale questions for 2026 investigators.

Ester local anesthetic (very short-acting)

A 2-chloro-substituted procaine analog with the fastest plasma cholinesterase hydrolysis among local anesthetics, used in obstetric epidural and short-procedure spinal anesthesia.

Abstract

Chloroprocaine (2-(diethylamino)ethyl 4-amino-2-chlorobenzoate; CAS 133-16-4; molecular formula C13H19ClN2O2; molecular weight 270.76) is an ester-class local anesthetic introduced in the 1950s (Nesacaine) as a 2-chloro analog of procaine. The 2-chloro substitution adjacent to the ester linkage substantially accelerates plasma cholinesterase hydrolysis, producing the shortest plasma half-life of any clinical local anesthetic (approximately 21 seconds, versus 1 minute for procaine and far longer for amides). The very short systemic exposure makes chloroprocaine the safest local anesthetic for fetal exposure during obstetric epidural anesthesia and a useful agent for short-procedure spinal anesthesia in ambulatory surgical centers where rapid offset and discharge readiness are operationally valuable. Mechanism is voltage-gated sodium channel block with state-dependent kinetics; potency is similar to procaine on a milligram basis and substantially less than amide agents. The historical association with neurotoxicity (cauda equina syndrome) traces to the bisulfite preservative formulation used in Nesacaine through the 1980s and a high-pH, sodium bisulfite preservative system that produced free radical injury to nerve roots when administered intrathecally; reformulation with EDTA preservative and subsequent preservative-free 1 percent and 3 percent preparations resolved the neurotoxicity concern, and chloroprocaine has returned to spinal anesthesia use in ambulatory surgery as an alternative to lidocaine spinal (which carries its own transient neurologic symptoms concern). Modern formulations are preservative-free or use methylparaben preservatives at concentrations below the historical threshold for nerve injury. Maximum recommended doses are 11 mg/kg without epinephrine and 14 mg/kg with epinephrine.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1319Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-1319

Chloroprocaine

Abstract

Read the full monograph